Regulatory Reference
FDA Drug Submission Types
NDA, ANDA, BLA, IND, 505(b)(2), and sNDA — every FDA drug approval pathway explained with requirements, timelines, and key differences. Free reference for regulatory affairs, BD, and clinical development teams.
Quick Answer
FDA drug approval pathways include IND (clinical authorization), NDA (new small molecules), ANDA (generics via bioequivalence), BLA (biologics under PHS Act Section 351), 505(b)(2) (hybrid NDAs relying on published or prior FDA data), and sNDA/sBLA supplements for post-approval changes. Standard PDUFA review goals are 12 months; Priority Review is 6 months. This free reference maps requirements, exclusivity, and timelines for regulatory affairs and BD teams.
Submission Types at a Glance
- Required before any clinical trial in the US
- 30-day FDA review clock (clinical hold window)
- Types: Commercial, Research, Treatment, Emergency
- Annual IND report required (within 60 days of anniversary)
- Filed under 21 CFR 312
- Full approval pathway for new small-molecule drugs
- Requires complete clinical safety & efficacy data
- Filed under 21 CFR 314
- Standard review: 12 months PDUFA goal
- Priority Review: 6 months PDUFA goal
- User fee (FY2025): ~$4.2 million
- Generic drug approval — relies on RLD's safety/efficacy data
- Requires bioequivalence (BE) studies only
- BE criteria: 90% CI of Cmax and AUC within 80–125%
- Para IV: patent challenge → 180-day first-generic exclusivity
- User fee (FY2025): ~$100,000
- Filed under 21 CFR 314 Subpart C
- Approval pathway for biological products
- Covers: mAbs, vaccines, blood products, gene therapies
- Filed under Section 351 of the PHS Act
- Biosimilar path: 351(k) abbreviated BLA
- Interchangeability: pharmacist substitution without prescriber intervention
- Review clock: same as NDA (6 or 12 months)
- Relies partly on existing published data or FDA prior findings
- Faster and less expensive than full 505(b)(1) NDA
- Uses: new formulation, route, indication, or combination
- Right of reference or published literature required
- Patent certification exposure same as ANDA Para IV
- Post-approval changes to approved NDA or BLA
- Prior Approval Supplement (PAS): FDA approval before change
- CBE-30: Changes Being Effected, 30-day notice to FDA
- CBE-0: Minor changes, immediate implementation allowed
- Common uses: new indication, new form, manufacturing change
IND — Investigational New Drug Application
Purpose: An IND authorizes clinical investigation of an unapproved drug or biologic in human subjects in the United States. Without an active IND, shipping an investigational drug across state lines for clinical testing is prohibited.
Required before: Phase I clinical trials in the US. Must be filed and in effect before first subject is dosed.
Key sections:
The IND must include preclinical pharmacology and toxicology data (animal studies supporting the proposed Phase I dose and duration), clinical protocols for proposed studies, investigator information (Form FDA 1572), and Chemistry, Manufacturing, and Controls (CMC) information for the investigational product.
IND types:
Commercial IND — filed by a sponsor intending to seek marketing approval. Research IND — filed by an investigator-sponsor for academic research. Treatment IND — allows use of an investigational drug in seriously ill patients outside clinical trials. Emergency IND — authorizes use in a single patient emergency before formal IND is in place.
Review clock: FDA has 30 days to review. If FDA does not place the IND on clinical hold within 30 days, the sponsor may proceed. Annual IND progress reports are required within 60 days of each anniversary of the IND effective date.
NDA — New Drug Application
Purpose: The NDA is the vehicle by which drug sponsors formally ask FDA to approve a new pharmaceutical for sale and marketing in the US. It contains the full clinical, nonclinical, and CMC data package demonstrating safety, efficacy, and quality.
Filed under: 21 CFR 314. Submitted in eCTD format organized in the five CTD modules.
CTD structure: Module 1 (administrative/regional), Module 2 (summaries/overviews), Module 3 (Quality/CMC), Module 4 (Nonclinical study reports), Module 5 (Clinical study reports).
Filing review: FDA has 60 days to assess completeness and decide whether to file the NDA. A refuse-to-file (RTF) action means the application lacks sufficient information for substantive review.
Review designation: Standard Review (12-month PDUFA goal) or Priority Review (6-month goal, for drugs offering major therapeutic advance). Special designations that may affect review include Fast Track, Breakthrough Therapy, and Accelerated Approval.
Outcome options: Approval, Complete Response Letter (CRL) — FDA's way of communicating deficiencies that must be resolved before approval can be granted.
Exclusivity: 5 years New Chemical Entity (NCE) exclusivity for new molecular entities; 3 years new clinical investigation exclusivity for new conditions of use.
ANDA — Abbreviated New Drug Application
Purpose: The ANDA pathway allows generic drug manufacturers to obtain approval by demonstrating that their product is bioequivalent to an already-approved Reference Listed Drug (RLD) — without repeating the full clinical development program.
Filed under: 21 CFR 314 Subpart C. Generic drugs are listed in the FDA's Orange Book.
Bioequivalence requirement: The 90% confidence interval for both Cmax (peak concentration) and AUC (area under the curve) must fall within 80–125% of the RLD. BE is typically demonstrated in a crossover PK study in healthy volunteers.
Patent certifications: ANDA applicants must certify their product's relationship to listed patents. A Paragraph IV certification (patent is invalid or not infringed) triggers a 30-month stay of approval and gives the first successful challenger 180 days of generic marketing exclusivity — a major competitive advantage.
What is not required: New clinical safety or efficacy studies. FDA relies on the RLD's approved data. The generic must be the same dosage form, route, strength, and condition of use as the RLD.
BLA — Biologics License Application
Purpose: The BLA is the approval pathway for biological products — including monoclonal antibodies, therapeutic proteins, vaccines, blood products, and gene therapies. FDA's Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) reviews BLAs depending on product type.
Filed under: Section 351 of the Public Health Service (PHS) Act.
Key difference from NDA: Biological products cannot be fully characterized by chemical structure alone. Manufacturing process is integral to the product — "the process is the product." BLAs therefore place greater emphasis on manufacturing process validation, comparability, and lot-to-lot consistency than NDAs.
Biosimilar pathway (351(k) BLA): An abbreviated BLA for products highly similar to an already-licensed reference product, with no clinically meaningful differences in safety, purity, or potency. Requires analytical, PK/PD, and clinical studies demonstrating biosimilarity.
Interchangeability: A higher standard than biosimilarity. An interchangeable biological product can be substituted by a pharmacist without prescriber intervention, analogous to generic substitution for small molecules. Requires additional switching studies.
Exclusivity: 12 years reference product exclusivity from first licensure; 4-year data exclusivity period during which biosimilar applications cannot be submitted.
505(b)(2) NDA — Hybrid Application
Purpose: The 505(b)(2) pathway allows a sponsor to submit an NDA that relies, at least in part, on published literature or FDA's previous findings of safety and efficacy for a listed drug — rather than conducting an entirely new clinical development program.
Advantage over full NDA: Significantly reduced clinical data requirements translate to lower development cost and shorter timelines compared to a 505(b)(1) NDA requiring fully independent clinical data.
Typical 505(b)(2) scenarios: A new formulation of an approved drug (e.g., extended-release of an IR product), a new route of administration, a new indication for an established drug, a fixed-dose combination of two approved drugs, or an improved delivery system.
Data reliance mechanism: The sponsor must either obtain a Right of Reference (ROR) from the original NDA holder, or rely on published scientific literature. FDA will "bridge" the reference product's safety/efficacy record to the new product through the sponsor's bridging data (usually PK bridging studies).
Patent considerations: Like ANDA applicants, 505(b)(2) sponsors must make patent certifications against listed patents of the referenced product. A Para IV certification can result in a 30-month litigation stay.
sNDA / sBLA — Supplemental Applications
Purpose: Post-approval changes to an approved NDA or BLA require a supplemental application. The type of supplement required depends on the significance of the proposed change.
Prior Approval Supplement (PAS): Required for major changes that may have a substantial potential to adversely affect drug identity, strength, quality, purity, or potency. FDA must approve before the change is implemented. Review goal: 6–10 months.
CBE-30 (Changes Being Effected in 30 Days): Moderate changes. Sponsor submits and may implement the change after 30 days if FDA does not place it on hold. Used for manufacturing changes with well-established risk profiles.
CBE-0 (Changes Being Effected Immediately): Minor changes with minimal risk. Sponsor may implement immediately and submit the supplement concurrently. Retrospective FDA review.
Common supplemental changes: New therapeutic indication (efficacy supplement), new patient population, new dosage form or strength, container closure change, labeling update, manufacturing site change, and process change post-approval.
NDA vs. ANDA vs. BLA — Key Differences
| Feature | NDA | ANDA | BLA |
|---|---|---|---|
| Product type | New small molecule (chemical) | Generic small molecule | Biological product |
| Clinical data required? | Yes — full safety & efficacy | No — BE studies only | Yes — full safety & efficacy |
| Legal basis | 21 CFR 314 (FDCA 505(b)(1)) | 21 CFR 314 Subpart C | PHS Act Section 351 |
| Exclusivity granted | 5 yrs (NCE) / 3 yrs (new clinical) | 180 days (Para IV first filer) | 12 yrs reference product |
| Typical review time | 6–12 months (PDUFA goal) | 10–30 months | 6–12 months (PDUFA goal) |
IND to Approval — Typical Timeline
From IND filing through NDA approval, the full development and review process typically spans 8–12 years.
Pharma & Regulatory Affairs Context
Submission pathway selection is a core strategic decision for BD, clinical development, and RA teams. A full 505(b)(1) NDA requires independent clinical data and commands NCE exclusivity; a 505(b)(2) can accelerate time-to-market by bridging to an approved reference product; ANDA and 351(k) biosimilar paths target LOE and patent-expiry windows.
Pair this guide with our Submission Timeline Builder for milestone planning, PDUFA Date Calculator for review-clock math, PDUFA Calendar 2026 for disclosed catalysts, and Clinical Trial Phases for IND-through-Phase III development context.
Evidence & Sources
- FDA: Types of Applications — NDA, ANDA, BLA, IND overview
- FDA: New Drug Application (NDA) — submission and review
- FDA: Abbreviated New Drug Application (ANDA) — generic approval
- FDA: Biologics License Applications (BLA) — CBER process
- FDA CDER Desk Reference Guide — PDUFA review milestones
Competitive landscape: FDA.gov (Types of Applications) is authoritative but fragmented across separate pages with no side-by-side NDA/ANDA/BLA comparison or supplement taxonomy. RAPS Regulatory Focus publishes editorial RA explainers behind membership paywalls without free cross-linked IND→NDA timelines. NovaPharmaNews combines submission-type cards, comparison tables, PDUFA clocks, exclusivity rules, and regulatory cluster links in one free reference — no login required.